News for Bio-Thera Solutions,Ltd. (688177.SS)

PR NewswireGUANGZHOU, China, July 16, 2025 GUANGZHOU, China, July 16, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biophar

PR NewswireGUANGZHOU, China, June 20, 2025 CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO®

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

PR NewswireGUANGZHOU, China, April 14, 2025 GUANGZHOU, China, April 14, 2025 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage bioph

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable medicines.

PR NewswireGUANGZHOU, China, Feb. 7, 2025 The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a b

PR NewswireGUANGZHOU, China, Dec. 24, 2024 GUANGZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biophar

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara ® (Ustekinumab) Biosimilar in Saudi Arabia

PR NewswireGUANGZHOU, China, Dec. 16, 2024 GUANGZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Bio-Thera Solutions, a commercial-stage biopharmaceutical compan

Japan's Food Immunomodulators market is projected to rise at a CAGR of 6.8% through 2034, the integration of advanced microbiome culture systems and...

Tumor necrosis factor inhibitor drugs industry is projected to witness a CAGR of 2.2% during the period 2024-2032. This growth can be attributed to...

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi ® (bevacizumab), a Biosimilar Referencing Avastin ®

Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

The Psoriasis Vulgaris treatment market is expected to increase due to the increasing geriatric population across the globe. Advances in technology,...

/PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative assets and biosimilars,...

Newark, New Castle, USA, April 28, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports study the Golimumab Market is expected to register...

/PRNewswire/ -- DelveInsight's 'Rheumatoid Arthritis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline...